RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
-
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California, United States, 90404
UC Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817
Sarah Cannon, SCRI Oncology Partners - Health One, Denver, Colorado, United States, 80218
Sarah Cannon, SCRI Oncology Partners, Sidney Kimmel Cancer Center - Thomas Jefferson Hospital, Philadelphia, Pennsylvania, United States, 19107
Sarah Cannon, SCRI Oncology Partners, Nashville, Tennessee, United States, 37203
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
RasCal Therapeutics, Inc.,
Pamela Munster, MD, STUDY_DIRECTOR, RasCal Therapeutics, Inc.
2025-09-01